Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid.
Omega-3 fatty acids have received increasing interest due to their effects in stabilizing plasmatic membranes and regulating cell signaling. The efficacy of omega-3 fatty acids in psychiatric disorders, in particular mood disorders, has been studied. There have been two trials on eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) in the treatment of borderline personality disorder (BPD). The present 12-week controlled trial aimed to assess the efficacy of the association of EPA and DHA with valproic acid, compared to single valproic acid, in 43 consecutive BPD outpatients. Participants were evaluated at baseline and after 12 weeks with: Clinical Global Impression - Severity (CGI-S), Hamilton Scales for depression and anxiety (HAM-D, HAM-A), Social and Occupational Functioning Assessment Scale (SOFAS), borderline personality disorder severity index (BPDSI), Barratt Impulsiveness Scale - version 11 (BIS-11), Modified Overt Aggression Scale (MOAS), Self-Harm Inventory (SHI) and Dosage Record Treatment Emergent Symptom Scale (DOTES).
['Bellino|Silvio|S|', 'Bozzatello|Paola|P|', 'Rocca|Giuseppe|G|', 'Bogetto|Filippo|F|']
D000328:Adult D018692:Antimanic Agents D001883:Borderline Personality Disorder D004359:Drug Therapy, Combination D015525:Fatty Acids, Omega-3 D005260:Female D006801:Humans D008297:Male D014635:Valproic Acid
efficacy omega-3 fatty acid Borderline personality disorder valproic acid psychiatric disorders eicosapentanoic acid docosahexanoic acid mood stabilizer tolerability